We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
- Authors
Orlowski, Robert Z; Nagler, Arnon; Sonneveld, Pieter; Bladé, Joan; Hajek, Roman; Spencer, Andrew; San Miguel, Jesús; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J; Suvorov, Alexander N; Zhuang, Sen H; Parekh, Trilok; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne; Harousseau, Jean-Luc
- Abstract
This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 25, p3892
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.10.5460